These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 850913)

  • 1. Characteristics and thrombogenicity of prothrombin complex concentrates.
    Sakuragawa N; Takahashi K; Hoshiyama M; Niiya K; Itoh M; Matsuoka M; Ohnishi Y
    Thromb Res; 1977 Feb; 10(2):315-8. PubMed ID: 850913
    [No Abstract]   [Full Text] [Related]  

  • 2. Prothrombin complex concentrates.
    Penner JA
    Bibl Haematol; 1977; 44():81-7. PubMed ID: 617787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates.
    Dusel CH; Grundmann C; Eich S; Seitz R; König H
    Blood Coagul Fibrinolysis; 2004 Jul; 15(5):405-11. PubMed ID: 15205589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: Prothrombin-complex concentrates and thromboses.
    N Engl J Med; 1974 Feb; 290(7):403-4. PubMed ID: 4810120
    [No Abstract]   [Full Text] [Related]  

  • 5. Commercial preparations of prothrombin complex. A clinical comparison.
    Gunay U; Choi HS; Maurer HS; Hruby M; Honig GR
    Am J Dis Child; 1973 Dec; 126(6):775-7. PubMed ID: 4759364
    [No Abstract]   [Full Text] [Related]  

  • 6. Christmas factor concentrates. The clinical use of several preparations.
    Tullis JL; Breen FA
    Bibl Haematol; 1970; 34():40-51. PubMed ID: 5436352
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate.
    Morfini M; Longo G; Berntorp E; Cinotti S; Filimberti E; Messori A; Nilsson IM; Rossi Ferrini P
    Thromb Res; 1993 Aug; 71(3):175-84. PubMed ID: 8211885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the mechanism of action and future of activated prothrombin complex concentrates.
    Turecek PL; Váradi K; Schwarz HP
    Curr Hematol Rep; 2004 Sep; 3(5):331-7. PubMed ID: 15341699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
    Hansson KM; Gustafsson D; Skärby T; Frison L; Berntorp E
    J Thromb Haemost; 2015 Jul; 13(7):1293-300. PubMed ID: 25944555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prothrombal: a new concentrate of human prothrombin complex for clinical use.
    Bruning PF; Loeliger EA
    Br J Haematol; 1971 Oct; 21(4):377-98. PubMed ID: 5001176
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.
    Martinowitz UP; Schulman S
    Acta Haematol; 1995; 94 Suppl 1():35-42. PubMed ID: 7571993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for highly purified products to treat hemophilia B.
    Scharrer I
    Acta Haematol; 1995; 94 Suppl 1():2-7. PubMed ID: 7571991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin complex concentrates: clinical use.
    Menache D
    Ann N Y Acad Sci; 1981; 370():747-56. PubMed ID: 6791551
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased fibrinopeptide A after prothrombin complex concentrates.
    Viganó S; Cattaneo M; Gervasoni W; Mannucci PM
    Thromb Haemost; 1980 Oct; 44(2):72-5. PubMed ID: 6779400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experiences with chromatographic DEAE adsorbed prothrombin complex for control of bleeding and multiple tooth extraction in hemophilia B patients.
    Onishi H; Izuchi K; Matsumoto T; Kato R; Kusunose K
    Nihon Ketsueki Gakkai Zasshi; 1971 Aug; 34(4):513-6. PubMed ID: 5317288
    [No Abstract]   [Full Text] [Related]  

  • 17. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prothrombin concentrates in treatment of Christmas disease and allied disorders.
    Breen FA; Tullis JL
    JAMA; 1969 Jun; 208(10):1848-52. PubMed ID: 5818828
    [No Abstract]   [Full Text] [Related]  

  • 19. Properties of factor IX concentrates.
    Berntorp E
    Acta Haematol; 1995; 94 Suppl 1():8-11. PubMed ID: 7571997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates.
    Sadeghi N; Iacobelli M; Vaziri B; Kahn D; Hoppensteadt D; Guler N; Fareed J
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):211-220. PubMed ID: 27553841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.